Concepts (181)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 39 | 2024 | 447 | 6.090 |
Why?
|
| Endoscopy | 9 | 2011 | 53 | 2.140 |
Why?
|
| Carcinoma, Ductal, Breast | 9 | 2021 | 15 | 1.810 |
Why?
|
| Mammary Glands, Human | 6 | 2011 | 18 | 1.710 |
Why?
|
| Mastectomy, Segmental | 8 | 2021 | 18 | 1.500 |
Why?
|
| Mastectomy | 5 | 2024 | 21 | 0.890 |
Why?
|
| Breast | 7 | 2021 | 52 | 0.800 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 3 | 2011 | 9 | 0.770 |
Why?
|
| Aged, 80 and over | 16 | 2024 | 1936 | 0.730 |
Why?
|
| Female | 40 | 2024 | 14627 | 0.720 |
Why?
|
| Medicare | 2 | 2024 | 119 | 0.590 |
Why?
|
| Aged | 17 | 2024 | 5216 | 0.550 |
Why?
|
| Humans | 42 | 2024 | 27101 | 0.540 |
Why?
|
| Middle Aged | 19 | 2022 | 6894 | 0.500 |
Why?
|
| Microwaves | 3 | 2009 | 9 | 0.460 |
Why?
|
| Nipples | 4 | 2009 | 5 | 0.430 |
Why?
|
| Adult | 16 | 2022 | 7488 | 0.410 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2020 | 312 | 0.410 |
Why?
|
| Hyperthermia, Induced | 2 | 2009 | 30 | 0.390 |
Why?
|
| Medicaid | 1 | 2011 | 52 | 0.370 |
Why?
|
| Quality Assurance, Health Care | 1 | 2011 | 62 | 0.370 |
Why?
|
| Therapeutic Irrigation | 4 | 2005 | 19 | 0.360 |
Why?
|
| Brachytherapy | 1 | 2011 | 50 | 0.360 |
Why?
|
| Carcinoma, Lobular | 1 | 2010 | 1 | 0.350 |
Why?
|
| Cosmetics | 1 | 2010 | 3 | 0.350 |
Why?
|
| General Surgery | 1 | 2011 | 53 | 0.350 |
Why?
|
| Mammaplasty | 1 | 2010 | 12 | 0.350 |
Why?
|
| Medical Oncology | 1 | 2011 | 86 | 0.340 |
Why?
|
| Clinical Competence | 1 | 2011 | 216 | 0.330 |
Why?
|
| Reconstructive Surgical Procedures | 2 | 2010 | 72 | 0.320 |
Why?
|
| Prospective Studies | 7 | 2022 | 1219 | 0.300 |
Why?
|
| Hyperplasia | 3 | 2020 | 27 | 0.280 |
Why?
|
| Neoplasm Staging | 5 | 2021 | 462 | 0.280 |
Why?
|
| Retrospective Studies | 6 | 2024 | 2450 | 0.280 |
Why?
|
| Mammography | 2 | 2010 | 79 | 0.270 |
Why?
|
| Prognosis | 5 | 2024 | 763 | 0.260 |
Why?
|
| Dermatologic Surgical Procedures | 1 | 2005 | 8 | 0.260 |
Why?
|
| Survival Rate | 3 | 2011 | 411 | 0.250 |
Why?
|
| Specimen Handling | 1 | 2005 | 30 | 0.250 |
Why?
|
| SEER Program | 1 | 2024 | 46 | 0.240 |
Why?
|
| Time-to-Treatment | 1 | 2024 | 26 | 0.240 |
Why?
|
| Postoperative Complications | 1 | 2009 | 605 | 0.230 |
Why?
|
| Exosomes | 2 | 2016 | 92 | 0.230 |
Why?
|
| Surgicenters | 1 | 2002 | 1 | 0.210 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2002 | 6 | 0.210 |
Why?
|
| Neoadjuvant Therapy | 2 | 2022 | 69 | 0.210 |
Why?
|
| Precancerous Conditions | 1 | 2003 | 33 | 0.210 |
Why?
|
| Mastitis | 1 | 2002 | 3 | 0.210 |
Why?
|
| Carcinoma in Situ | 1 | 2003 | 44 | 0.210 |
Why?
|
| Catheter Ablation | 1 | 2005 | 220 | 0.200 |
Why?
|
| Treatment Outcome | 4 | 2011 | 2280 | 0.200 |
Why?
|
| MicroRNAs | 2 | 2016 | 281 | 0.200 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2022 | 36 | 0.190 |
Why?
|
| Appendiceal Neoplasms | 1 | 2021 | 5 | 0.190 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2021 | 31 | 0.180 |
Why?
|
| Disease-Free Survival | 3 | 2011 | 225 | 0.180 |
Why?
|
| Butylene Glycols | 1 | 2020 | 3 | 0.170 |
Why?
|
| Glucosides | 1 | 2020 | 8 | 0.170 |
Why?
|
| Lignans | 1 | 2020 | 10 | 0.170 |
Why?
|
| Premenopause | 1 | 2020 | 20 | 0.170 |
Why?
|
| Young Adult | 4 | 2022 | 2625 | 0.170 |
Why?
|
| Follow-Up Studies | 3 | 2020 | 985 | 0.170 |
Why?
|
| Combined Modality Therapy | 2 | 2011 | 290 | 0.160 |
Why?
|
| Endoscopes | 2 | 2011 | 6 | 0.150 |
Why?
|
| United States | 3 | 2024 | 2060 | 0.140 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2015 | 445 | 0.120 |
Why?
|
| Biopsy | 2 | 2005 | 201 | 0.120 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2015 | 104 | 0.120 |
Why?
|
| Neoplasm Metastasis | 1 | 2015 | 150 | 0.120 |
Why?
|
| Docosahexaenoic Acids | 1 | 2015 | 91 | 0.110 |
Why?
|
| Risk Factors | 4 | 2024 | 2030 | 0.110 |
Why?
|
| Receptor, ErbB-2 | 2 | 2024 | 32 | 0.110 |
Why?
|
| Biomarkers, Tumor | 1 | 2016 | 377 | 0.110 |
Why?
|
| Biopsy, Needle | 2 | 2003 | 47 | 0.100 |
Why?
|
| Macrophage Migration-Inhibitory Factors | 1 | 2011 | 8 | 0.090 |
Why?
|
| HLA-A Antigens | 1 | 2011 | 24 | 0.090 |
Why?
|
| Lymphatic Metastasis | 1 | 2011 | 119 | 0.090 |
Why?
|
| Cell Line, Tumor | 4 | 2016 | 1267 | 0.090 |
Why?
|
| Reproducibility of Results | 2 | 2015 | 750 | 0.090 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2009 | 23 | 0.080 |
Why?
|
| Multicenter Studies as Topic | 1 | 2009 | 43 | 0.080 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2009 | 26 | 0.080 |
Why?
|
| Breast Diseases | 1 | 2009 | 7 | 0.080 |
Why?
|
| Spasm | 1 | 2009 | 4 | 0.080 |
Why?
|
| Postoperative Nausea and Vomiting | 1 | 2009 | 2 | 0.080 |
Why?
|
| Antibodies, Monoclonal | 1 | 2011 | 317 | 0.080 |
Why?
|
| Lymphedema | 1 | 2009 | 14 | 0.080 |
Why?
|
| Bronchoscopy | 1 | 2009 | 34 | 0.080 |
Why?
|
| Signal Transduction | 1 | 2015 | 1377 | 0.080 |
Why?
|
| Neoplasm Grading | 2 | 2021 | 104 | 0.080 |
Why?
|
| Receptors, Estrogen | 2 | 2022 | 42 | 0.080 |
Why?
|
| Equipment Design | 1 | 2009 | 211 | 0.080 |
Why?
|
| Pain, Postoperative | 1 | 2009 | 59 | 0.080 |
Why?
|
| Fiber Optic Technology | 1 | 2008 | 14 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2009 | 364 | 0.070 |
Why?
|
| Lymph Node Excision | 1 | 2007 | 96 | 0.070 |
Why?
|
| Survival Analysis | 1 | 2007 | 278 | 0.070 |
Why?
|
| Recurrence | 1 | 2007 | 316 | 0.070 |
Why?
|
| False Positive Reactions | 1 | 2005 | 30 | 0.060 |
Why?
|
| Case-Control Studies | 2 | 2019 | 705 | 0.060 |
Why?
|
| Surgical Flaps | 1 | 2005 | 22 | 0.060 |
Why?
|
| Adolescent | 2 | 2022 | 2987 | 0.060 |
Why?
|
| Cryosurgery | 1 | 2005 | 19 | 0.060 |
Why?
|
| Laser Therapy | 1 | 2005 | 30 | 0.060 |
Why?
|
| Office Visits | 1 | 2004 | 8 | 0.060 |
Why?
|
| Multivariate Analysis | 2 | 2021 | 299 | 0.060 |
Why?
|
| Incidence | 1 | 2005 | 553 | 0.060 |
Why?
|
| Mastectomy, Radical | 1 | 2003 | 1 | 0.050 |
Why?
|
| Tamoxifen | 1 | 2003 | 31 | 0.050 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2003 | 26 | 0.050 |
Why?
|
| Suction | 1 | 2003 | 10 | 0.050 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2006 | 375 | 0.050 |
Why?
|
| Risk Assessment | 1 | 2005 | 595 | 0.050 |
Why?
|
| Papilloma | 1 | 2002 | 2 | 0.050 |
Why?
|
| Blood | 1 | 2002 | 33 | 0.050 |
Why?
|
| Insurance, Health | 1 | 2002 | 51 | 0.050 |
Why?
|
| Radionuclide Imaging | 1 | 2002 | 56 | 0.050 |
Why?
|
| Home Care Services | 1 | 2002 | 37 | 0.050 |
Why?
|
| Endothelial Cells | 2 | 2015 | 331 | 0.050 |
Why?
|
| Receptors, Progesterone | 1 | 2022 | 17 | 0.050 |
Why?
|
| Patient Satisfaction | 1 | 2002 | 90 | 0.050 |
Why?
|
| Reference Values | 1 | 2002 | 199 | 0.050 |
Why?
|
| Cytodiagnosis | 1 | 2001 | 12 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2002 | 191 | 0.050 |
Why?
|
| Attitude of Health Personnel | 1 | 2002 | 139 | 0.050 |
Why?
|
| Time Factors | 1 | 2005 | 1570 | 0.050 |
Why?
|
| Mass Screening | 1 | 2002 | 148 | 0.050 |
Why?
|
| Diagnosis, Differential | 1 | 2002 | 367 | 0.050 |
Why?
|
| Sensitivity and Specificity | 1 | 2002 | 508 | 0.050 |
Why?
|
| Hormones | 1 | 2021 | 41 | 0.050 |
Why?
|
| Intraoperative Care | 1 | 2020 | 22 | 0.050 |
Why?
|
| Mice | 3 | 2016 | 4470 | 0.040 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2020 | 60 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2021 | 217 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2021 | 189 | 0.040 |
Why?
|
| Flax | 1 | 2020 | 2 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2021 | 251 | 0.040 |
Why?
|
| Sex Factors | 1 | 2021 | 452 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2020 | 396 | 0.040 |
Why?
|
| Antineoplastic Agents | 1 | 2002 | 658 | 0.030 |
Why?
|
| Culture Media, Conditioned | 1 | 2016 | 31 | 0.030 |
Why?
|
| Heterografts | 1 | 2016 | 62 | 0.030 |
Why?
|
| Animals | 3 | 2016 | 10074 | 0.030 |
Why?
|
| ROC Curve | 1 | 2016 | 139 | 0.030 |
Why?
|
| rab27 GTP-Binding Proteins | 1 | 2015 | 5 | 0.030 |
Why?
|
| Transendothelial and Transepithelial Migration | 1 | 2015 | 5 | 0.030 |
Why?
|
| Aptamers, Nucleotide | 1 | 2015 | 13 | 0.030 |
Why?
|
| MCF-7 Cells | 1 | 2015 | 33 | 0.030 |
Why?
|
| Biological Transport | 1 | 2015 | 112 | 0.030 |
Why?
|
| E-Selectin | 1 | 2015 | 27 | 0.030 |
Why?
|
| rab GTP-Binding Proteins | 1 | 2015 | 33 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2015 | 131 | 0.030 |
Why?
|
| Cell Adhesion | 1 | 2015 | 133 | 0.030 |
Why?
|
| Neovascularization, Physiologic | 1 | 2015 | 123 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2015 | 264 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2015 | 177 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2016 | 440 | 0.030 |
Why?
|
| Genetic Therapy | 1 | 2015 | 116 | 0.030 |
Why?
|
| Antibody Affinity | 1 | 2011 | 12 | 0.020 |
Why?
|
| HLA-A2 Antigen | 1 | 2011 | 17 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2016 | 1405 | 0.020 |
Why?
|
| Antibody Specificity | 1 | 2011 | 113 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2011 | 313 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2011 | 251 | 0.020 |
Why?
|
| Kinetics | 1 | 2011 | 538 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2011 | 589 | 0.020 |
Why?
|
| Cell Survival | 1 | 2011 | 395 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2011 | 674 | 0.020 |
Why?
|
| Protein Binding | 1 | 2011 | 636 | 0.020 |
Why?
|
| Cell Line | 1 | 2011 | 681 | 0.020 |
Why?
|
| Peptides | 1 | 2011 | 280 | 0.020 |
Why?
|
| Apoptosis | 1 | 2011 | 740 | 0.020 |
Why?
|
| Epirubicin | 1 | 2006 | 1 | 0.020 |
Why?
|
| Taxoids | 1 | 2006 | 36 | 0.020 |
Why?
|
| Male | 1 | 2021 | 13013 | 0.020 |
Why?
|
| Necrosis | 1 | 2004 | 81 | 0.010 |
Why?
|
| Linear Models | 1 | 2004 | 201 | 0.010 |
Why?
|
| Expert Testimony | 1 | 2002 | 7 | 0.010 |
Why?
|
| Risk | 1 | 2002 | 133 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2002 | 205 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 2002 | 241 | 0.010 |
Why?
|